Overview

Dose-Ranging Study of Pradefovir in Patients With Compensated Hepatitis B

Status:
Completed
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
- Compare the safety of four oral doses of pradefovir after 48 weeks of treatment - Select the dose of pradefovir for Phase 3 studies
Phase:
Phase 2
Details
Lead Sponsor:
Bausch Health Americas, Inc.
Valeant Pharmaceuticals International, Inc.
Treatments:
Adefovir
Adefovir dipivoxil
Pradefovir